Asma With Badge In Fumehood Resized

Making mini tumours to learn how to personalise treatment

Amanda Swain Headshot
Dr Amanda Swain

Grant information

Institution -  Institute of Cancer Research  
Lead Researcher -  Dr Amanda Swain  
Grant Award- £474,465.00
Duration of Funding - 2019-2023
Status - Complete
Reference -  RIA17-ST2-019
Using genetic models, we will be able to determine which mutations make prostate cancer sensitive to which therapies.
Dr Amanda Swain

Why did we fund this project?

  • Every prostate cancer is different, and so the best treatment for one man may not be the best treatment for another.
  • As prostate cancer develops, the DNA in cancer cells undergoes changes, called mutations, which promote the growth and spread of cancer.
  • Mutations are different in each man's prostate cancer, and this can alter how effective treatments are.
  • Amanda and team wanted to work out exactly how different mutations in cancer cells affect how well treatments work.
  • In particular, they focused on a type of prostate cancer treatment that works by stopping cancer cells from repairing themselves (such as Olaparib). The team proposed that certain mutations might make this type of treatment more effective.
  • Their findings could be used to predict which treatments will work best based on the mutations in a man's prostate cancer, meaning men can receive the most effective therapy tailored to them.

What did the team do?

Pipetting
  • Amanda and team grew 'mini-tumours' in the lab from prostate cancer cells, and intentionally created mutations commonly found in prostate cancer.
  • The team studied how mini-tumours with various mutations responded to treatments.

What did the team achieve?

  • The team identified mutations that changed how the mini-tumours responded to treatment.
  • Some mutations made the mini-tumours more susceptible to treatments like Olaparib, that stop cancer cells from repairing themselves. 
  • Excitingly, the team found when treatments didn't work on mini-tumours with certain mutations, often a combination of multiple treatments was effective.

How will this benefit men?

  • The team's work could help to predict which treatments will work in which men, based on the mutations in their prostate cancer cells.
  • With further validation, this insight could help guide treatment decisions to ensure men get the most effective treatment personalised for them.
  • The team's next steps are to use their insight to guide recruitment for clinical trials of new prostate cancer drugs, ensuring the men who are most likely to benefit are included in the trial.
Medical Appointment Test Doctor Adobestock 257047144

Help us fund more lifesaving research like this...

Your support helps us fund pioneering research, so we can work towards a future where men's lives aren't limited by prostate cancer.

Get Involved